Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2012-01630 | Registry Identifier | NCI CTRP |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant.
The goal of this clinical research study is to learn if thiotepa, busulfan, and clofarabine, when given before an allogeneic (bone marrow , blood, or cord blood cells) or haploidentical (bone marrow) stem cell transplantation can help to control cancers of the bone marrow and lymph node system. The safety of this treatment will also be studied.
This is an investigational study. Thiotepa and clofarabine are FDA approved and commercially available for the treatment of leukemia. Busulfan is FDA approved and commercially available for use in stem cell transplantation. The combination of thiotepa, clofarabine, and busulfan together with a stem cell transplant is investigational.
Up to 60 participants will take part in this study. All will be enrolled at M. D. Anderson.
The Study Drugs:
Thiotepa and busulfan are designed to bind to DNA (genetic material of cells), which may cause cancer cells to die. They are commonly used in stem cell transplants.
Clofarabine is designed to interfere with the growth and development of cancer cells.
Study Drug Administration:
If you are found to be eligible to take part in this study, you will begin receiving the study drugs before you receive the stem cell transplant.
The days before you receive your stem cells are called minus days, such as Day -2 and Day -1. The day you receive the stem cells is called Day 0. The days after you receive the stem cells are called plus days, such as Day +1 and Day +2.
On Day -8 (8 days before you receive the stem cell transplant), you will receive thiotepa through a central venous catheter (CVC) over 2 hours. A CVC is a sterile, flexible tube that will be placed into a large vein while you are under local anesthesia. Your doctor will explain this procedure to you in more detail, and you will be required to sign a separate consent form for this procedure.
On Day -7, you will receive busulfan through a CVC. This dose of busulfan is a low level "test" dose to check how your blood levels change over time. This information will be used to decide the next dose level of busulfan.
Blood (about 1 teaspoon each time) will be drawn 6-11 times total over Days -7 and -5 for pharmacokinetic (PK) testing. PK testing measures the amount of busulfan in the body at different time points. This PK testing will be done to find the dose of busulfan needed for your body size on the other days that you receive busulfan. A heparin lock line will be placed in a vein to lower the number of needed sticks performed for draws. If you cannot have the blood level tests performed for any reason, you will receive the standard busulfan dose.
On Days -6, -5, -4, and -3, you will receive clofarabine through a CVC over 1 hour.
On Days -5, -4, and -3, you will receive busulfan through a CVC over 3 hours.
If you will receive stem cells from a donor whose cells do not match your own cells closely, on Days -4 and -3 you will also receive antithymocyte globulin (ATG) by vein over 4 hours. This will help to reduce the risk of your body rejecting the transplant. If your transplant will involve haploidentical stem cells, you will not receive ATG on Days -4 and -3.
On Days -2 and -1, you will "rest," which means you will not be given any drugs, but your CVC will remain in place.
If thiotepa is not available:
If thiotepa is not available, or if you doctor thinks it is in your best interest, you will receive the following study drugs and total body irradiation (TBI) before you receive the stem cell transplant. TBI involves the delivery of high doses of radiation designed to destroy cancer cells and/or lower the immune system in order to lower the risk of the body rejecting the new stem cells.
Between Days -16 and -7, you will receive a low-level "test" dose of busulfan by vein over about 45 minutes to 1 hour. Test doses are used to study how your body breaks down busulfan and decide the dose of busulfan that you will receive. You may receive the test dose before Day -6 as an outpatient in the clinic, or on Day -6 as an inpatient in the hospital.
Blood (about 1 teaspoon each time) will then be drawn for PK testing up to 11 times over the 11 hours after the busulfan test dose and on Day -4. PK testing measures the amount of study drug in the body at different time points. The study staff will tell you more about the PK testing schedule.
A heparin lock line will be placed in your vein before the PK testing to lower the number of needle sticks needed for these draws. If for any reason it is not possible for the PK tests to be performed, you will receive the standard dose of busulfan.
On Day -7 or Day -6, you will be admitted to the hospital and given fluids through a CVC to hydrate you.
On Days -5, -4, -3, and -2, you will receive clofarabine through a CVC over 1 hour.
On Days -4, -3, and -2, you will receive busulfan through a CVC over 3 hours.
If you will receive stem cells from a donor whose cells do not match your own cells closely, on Days -3 and -2 you will also receive antithymocyte globulin (ATG) by vein over 4 hours. This will help to reduce the risk of your body rejecting the transplant. If your transplant will involve haploidentical stem cells, you will not receive ATG on Days -3 and -2.
On Day -1, you will receive TBI one time.
Stem Cell Transplant:
On Day 0, you will have an allogeneic or haploidentical stem cell transplant through the CVC. Allogeneic stem cells come from a donor whose cells closely match your own cells. Haploidentical stem cells come from a donor whose cells do not match your own cells as closely, but they are specially processed to help prevent graft versus host disease (GVHD).
Receiving stem cells is similar to receiving a blood transfusion. The time required to receive the stem cells will depend on the type of cells you are receiving. Receiving cord blood stem cells can take several minutes. Receiving bone marrow and blood stem cells may take several hours.
You will receive G-CSF (filgrastim) (which helps to produce white blood cells) as an injection under the skin once a day, starting 1 week after the transplant, until your blood cell levels return to normal.
You will receive drugs (mycophenolate mofetil (MMF), tacrolimus and/or methotrexate) to help prevent side effects, such as GVHD. You will receive methylprednisolone if you develop GVHD.
You will stay in the hospital for about 4 weeks after the stem cell transplantation.
If you had a haploidentical stem cell transplant, on Days 3 and 4 after your stem cell transplant, you will receive cyclophosphamide through a CVC over 3 hours. Mesna will be given by vein at the same time you are given each dose of cyclophosphamide, to help protect your bladder from bleeding.
Study Visits:
Beginning on Day -9, once a day while you are in the hospital:
After you are out of the hospital, 2 times a month until it has been 100 days after the transplant:
About 1, 3, 6, and 12 months after the transplant, blood (about 4 tablespoons) will be drawn to check the status of the disease. You will also have bone marrow aspirations to check the status of the disease. You will also have a physical exam.
If the doctor thinks it is necessary, you may have extra tests and procedures.
Length of Study:
You will be on study for about 1 year. You will be taken off study if the disease gets worse or needs further treatment.
Follow-Up:
If you live close to M. D. Anderson, you will return to the clinical once every several months for a physical exam. At these visits, blood (about 3 teaspoons) will be drawn for routine tests.
You and/or your local doctor will be called every several months and asked about your health status and if the leukemia or MDS has come back.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Thio-Clo-Bu with Allo SCT | Experimental | Pre-transplant conditioning regimen: Thiotepa (Thio) + Clofarabine (Clo) + Busulfan (Blu) + Allogeneic Stem Cell Transplantation (Allo SCT) + ATG + G-CSF Post haploidentical stem cell transplant participants: Cyclophosphamide 50 mg/kg by vein on Days + 3 and + 4. Mesna 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Thiotepa | Drug | 5 mg/kg through a central venous catheter (CVC) over 2 hours on Day -8. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Survival Rate at 100 Days Post-transplant | The toxicities will be monitored and scored on a daily basis following the methods of Simon R. Practical Bayesian Guideline for Phase IIB Clinical Trials. A Bayesian stopping rule will be used to stop the trial if there is a 90% chance that the true toxicity rate exceeds the target toxicity rate of 0.25. | 100 days post-transplant |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Disease Free Survival | Kaplan-Meier product limit method to estimate the disease free survival. | Up to 2 years post transplant |
| Overall Survival Rate | Overall Survival Rate will be estimated using the Kaplan-Meier method. |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kris M. Mahadeo, MD | M.D. Anderson Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | United States |
Not provided
| Label | URL |
|---|---|
| University of Texas MD Anderson Cancer Center Website | View source |
Not provided
Of the 60 participants enrolled, 2 participants did not proceed to transplant no data were collected for those two participants
This study received IRB approval October 1, 2008 and was opened to recruitment March 2, 2009. The study remained open to recruitment until August 4, 2015. The study was terminated by the local IRB on April 09, 2019.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Conditioning Reg- Thiotepa, Busulfan, and Clofarabine | Single arm study |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Nov 11, 2013 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Clofarabine | Drug | 40 mg/m^2 through a central venous catheter (CVC) over 1 hour daily on 4 consecutive days (Days -6 through -3). |
|
|
| Busulfan | Drug | Test dose of 0.5 mg/kg through a central venous catheter (CVC)over 30 minutes on Day -7. High dose 5,000 µMol-min through a central venous catheter (CVC) over 3 hours on Days -5, -4, and -3. |
|
|
| Allogeneic Stem Cell Transplantation | Procedure | Infusion of stem cells through through a central venous catheter (CVC) On Day 0. |
|
|
| Thymoglobulin (ATG) | Drug | 1.25 mg/kg by vein on Day -4 and 1.75 mg/kg on Day -3. |
|
|
| G-CSF (Filgrastim) | Drug | 5 µg/kg Injection under the skin once a day, starting 1 week after transplant, until blood cell levels return to normal. |
|
|
| Tacrolimus | Drug | Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered as indicated after transplant day 90, if no GVHD is present. Tacrolimus is adjusted trough level of 5-15 ng/mL. |
|
|
| Methotrexate | Drug | 5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant. The Day 11 methotrexate dose may be held as indicated if mucositis is present. |
|
| Cyclophosphamide | Drug | Post haploidentical stem cell transplant participants: 50 mg/kg by vein on Days + 3 and + 4. |
|
|
| Mesna | Drug | Post haploidentical stem cell transplant participants: 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses. |
|
|
| Up to 3 years post transplant |
| Graft vs Host Disease (GVHD) | Severity of toxicities graded according to the NCI Common Toxicity Criteria Adverse Effects (CTCAE) v3.0. Standard reporting guidelines followed for adverse events. Safety data summarized by category, severity and frequency. | Up to 30 days post transplant |
| Engraftment | Engraftment is most commonly defined as the first of three consecutive days of achieving a sustained peripheral blood neutrophil count of >500 × 10^6/L . | up to 100 days post transplant |
| Number of Participants With Serious Adverse Events | Severity of toxicities graded according to the NCI Common Toxicity Criteria Adverse Effects (CTCAE) v3.0. Standard reporting guidelines followed for adverse events. Safety data summarized by category, severity and frequency. | up to 30 days post transplant |
| Relapse Rate of Participants Treated With Thiotepa, Busulfan, and Clofarabine | Relapse Rate will be estimated using the Kaplan-Meier method. | Up to 2 years post transplant |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Two participants did not proceed to transplant no data were collected for those two participants
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Conditioning Reg- Thiotepa, Busulfan, and Clofarabine | The 5 mg/kg over 1 hr. Busulfan was administered x 3 days over 3 hr to a daily AUC of 5,000 mcMol-min +/-10%. Clofarabine 40mg/m2 was infused over 1 hr daily x 4 days |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Survival Rate at 100 Days Post-transplant | The toxicities will be monitored and scored on a daily basis following the methods of Simon R. Practical Bayesian Guideline for Phase IIB Clinical Trials. A Bayesian stopping rule will be used to stop the trial if there is a 90% chance that the true toxicity rate exceeds the target toxicity rate of 0.25. | Posted | Count of Participants | Participants | 100 days post-transplant |
|
|
| |||||||||||||||||||||||||||
| Secondary | Number of Participants With Disease Free Survival | Kaplan-Meier product limit method to estimate the disease free survival. | Posted | Count of Participants | Participants | Up to 2 years post transplant |
|
| ||||||||||||||||||||||||||||
| Secondary | Overall Survival Rate | Overall Survival Rate will be estimated using the Kaplan-Meier method. | Posted | Median | Full Range | days | Up to 3 years post transplant |
|
| |||||||||||||||||||||||||||
| Secondary | Graft vs Host Disease (GVHD) | Severity of toxicities graded according to the NCI Common Toxicity Criteria Adverse Effects (CTCAE) v3.0. Standard reporting guidelines followed for adverse events. Safety data summarized by category, severity and frequency. | Posted | Count of Participants | Participants | Up to 30 days post transplant |
|
| ||||||||||||||||||||||||||||
| Secondary | Engraftment | Engraftment is most commonly defined as the first of three consecutive days of achieving a sustained peripheral blood neutrophil count of >500 × 10^6/L . | Posted | Count of Participants | Participants | up to 100 days post transplant |
|
| ||||||||||||||||||||||||||||
| Secondary | Number of Participants With Serious Adverse Events | Severity of toxicities graded according to the NCI Common Toxicity Criteria Adverse Effects (CTCAE) v3.0. Standard reporting guidelines followed for adverse events. Safety data summarized by category, severity and frequency. | Posted | Count of Participants | Participants | up to 30 days post transplant |
|
| ||||||||||||||||||||||||||||
| Secondary | Relapse Rate of Participants Treated With Thiotepa, Busulfan, and Clofarabine | Relapse Rate will be estimated using the Kaplan-Meier method. | Posted | Count of Participants | Participants | Up to 2 years post transplant |
|
|
Adverse events that were related to the preparative regimen and stem cell infusion unil 30 days post transplant.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Conditioning Reg- Thiotepa, Busulfan, and Clofarabine | The 5 mg/kg over 1 hr. Busulfan was administered x 3 days over 3 hr to a daily AUC of 5,000 mcMol-min +/-10%. Clofarabine 40mg/m2 was infused over 1 hr daily x 4 days | 16 | 58 | 52 | 58 | 57 | 58 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| ARDS- Acute respiratory Distress Syndrome | Respiratory, thoracic and mediastinal disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Febrile Neutropenia | Blood and lymphatic system disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Ejection fraction decreased | Cardiac disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| DAH-diffuse alveolar hemorrhage | Respiratory, thoracic and mediastinal disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| ALK increase | Investigations | (CTCAE) v3.0 | Systematic Assessment |
| |
| Allergic reaction | Immune system disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| ALT increase | Investigations | (CTCAE) v3.0 | Systematic Assessment |
| |
| Hydrocephalus | Nervous system disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Creatinine Increased | Investigations | (CTCAE) v3.0 | Systematic Assessment |
| |
| Headache | Nervous system disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Hemorrhagic Cystitis | Renal and urinary disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Low granulocyte | Blood and lymphatic system disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Pneumonitis | Respiratory, thoracic and mediastinal disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Pulmonary edema | Respiratory, thoracic and mediastinal disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| T bilirubin increased | Investigations | (CTCAE) v3.0 | Systematic Assessment |
| |
| VOD | Hepatobiliary disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Rash | Skin and subcutaneous tissue disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Encephalopathy | Nervous system disorders | (CTCAE) v3.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abodominal Pain | Gastrointestinal disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| ALK increased | Investigations | (CTCAE) v3.0 | Systematic Assessment |
| |
| ALT increase | Investigations | (CTCAE) v3.0 | Systematic Assessment |
| |
| AMS- altered mental status | Nervous system disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Bleeding | Blood and lymphatic system disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Blurred Vision | Eye disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Bone Pain | Musculoskeletal and connective tissue disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Broncholitis Obliterans | Respiratory, thoracic and mediastinal disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Cardiomyopathy | Cardiac disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Cellulitis | Skin and subcutaneous tissue disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Confusion | Nervous system disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Creatinine Increased | Investigations | (CTCAE) v3.0 | Systematic Assessment |
| |
| Cystitis noninfective | Renal and urinary disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| DAH-diffuse alveolar hemorrhage | Respiratory, thoracic and mediastinal disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Diarrhea | Gastrointestinal disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Diplopia | Nervous system disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Dry eye | Eye disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Ejection fraction decreased | Cardiac disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Dysrhythmia | Cardiac disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Fever | General disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Flu like symdrome | Musculoskeletal and connective tissue disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Fluid overload | General disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Gastrointestinal bleeding | Gastrointestinal disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Generalized muscle weakness | Musculoskeletal and connective tissue disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Hallucination | Psychiatric disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Hand Foot syndrom | Skin and subcutaneous tissue disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Headache | Nervous system disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Hematochezia | Gastrointestinal disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Hemorrhagic Cystitis | Renal and urinary disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| HSCT related microangiopathy (TA-TMA) | Blood and lymphatic system disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Hyperglycemia | Metabolism and nutrition disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Hypertension | Vascular disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Hypotension | Vascular disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Infection | Infections and infestations | (CTCAE) v3.0 | Systematic Assessment |
| |
| Low platelet | Investigations | (CTCAE) v3.0 | Systematic Assessment |
| |
| Lower GI track obstruction | Gastrointestinal disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Neuropathy | Nervous system disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Oral mucositis | Gastrointestinal disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Pericarditis | Cardiac disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Pneumonitis | Respiratory, thoracic and mediastinal disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Pruritis | Skin and subcutaneous tissue disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Rash | Skin and subcutaneous tissue disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Secondary graft failure | Blood and lymphatic system disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| Seizure | Nervous system disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| SK OTH | Skin and subcutaneous tissue disorders | (CTCAE) v3.0 | Systematic Assessment |
| |
| T bilirubin increased | Investigations | (CTCAE) v3.0 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | (CTCAE) v3.0 | Systematic Assessment |
|
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Kris M Mahadeo, Associate Professor, Pediatrics - Patient Care | UT MD Anderson Cancer Center | (713) 792-2873 | kmmahadeo@mdanderson.org |
| Mar 11, 2020 |
| Prot_SAP_000.pdf |
| ID | Term |
|---|---|
| D007938 | Leukemia |
| D008223 | Lymphoma |
| D009369 | Neoplasms |
| ID | Term |
|---|---|
| D009370 | Neoplasms by Histologic Type |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D013852 | Thiotepa |
| D000102 | Acetyl-CoA C-Acyltransferase |
| D000077866 | Clofarabine |
| D006997 | Hypochlorous Acid |
| D002066 | Busulfan |
| C512542 | thymoglobulin |
| D000961 | Antilymphocyte Serum |
| D016179 | Granulocyte Colony-Stimulating Factor |
| D000069585 | Filgrastim |
| D016559 | Tacrolimus |
| D008727 | Methotrexate |
| D003520 | Cyclophosphamide |
| D015080 | Mesna |
| ID | Term |
|---|---|
| D063088 | Phosphoramides |
| D009943 | Organophosphorus Compounds |
| D009930 | Organic Chemicals |
| D013721 | Triethylenephosphoramide |
| D001388 | Aziridines |
| D001389 | Azirines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D000217 | Acyltransferases |
| D014166 | Transferases |
| D004798 | Enzymes |
| D045762 | Enzymes and Coenzymes |
| D000227 | Adenine Nucleotides |
| D011685 | Purine Nucleotides |
| D011687 | Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D001087 | Arabinonucleosides |
| D009705 | Nucleosides |
| D009706 | Nucleic Acids, Nucleotides, and Nucleosides |
| D009711 | Nucleotides |
| D012265 | Ribonucleotides |
| D000148 | Acids, Noncarboxylic |
| D000143 | Acids |
| D007287 | Inorganic Chemicals |
| D017606 | Chlorine Compounds |
| D017382 | Reactive Oxygen Species |
| D005609 | Free Radicals |
| D010087 | Oxides |
| D017601 | Oxygen Compounds |
| D002072 | Butylene Glycols |
| D006018 | Glycols |
| D000438 | Alcohols |
| D008698 | Mesylates |
| D000476 | Alkanesulfonates |
| D017738 | Alkanesulfonic Acids |
| D000473 | Alkanes |
| D006839 | Hydrocarbons, Acyclic |
| D006838 | Hydrocarbons |
| D013451 | Sulfonic Acids |
| D013456 | Sulfur Acids |
| D013457 | Sulfur Compounds |
| D007106 | Immune Sera |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
| D003115 | Colony-Stimulating Factors |
| D006023 | Glycoproteins |
| D006001 | Glycoconjugates |
| D002241 | Carbohydrates |
| D016298 | Hematopoietic Cell Growth Factors |
| D016207 | Cytokines |
| D036341 | Intercellular Signaling Peptides and Proteins |
| D010455 | Peptides |
| D001685 | Biological Factors |
| D018942 | Macrolides |
| D007783 | Lactones |
| D000630 | Aminopterin |
| D011622 | Pterins |
| D011621 | Pteridines |
| D010752 | Phosphoramide Mustards |
| D009588 | Nitrogen Mustard Compounds |
| D009150 | Mustard Compounds |
| D006846 | Hydrocarbons, Halogenated |
| D013438 | Sulfhydryl Compounds |
Not provided
Not provided
| Unknown or Not Reported |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|
| Title | Denominators | Categories |
|---|
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|